(1442) NGS-based MRD assessment refines prognostication after venetoclax-based first-line combinations for chronic lymphocytic leukemia: A prospective analysis of the phase 3 GAIA/CLL13 trial

Primary Author / Presenter(s)

• MF

  Moritz Fürstenau, MD

  Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne and Duesseldorf, German CLL Study Group, Faculty of Medicine and University Hospital Cologne, University of Cologne
  Cologne, Germany